Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk

Yoshida, Takeshi; Okamoto, Isamu; Okabe, Takafumi; Iwasa, Tsutomu; Satoh, Taroh; Nishio, Kazuto; Fukuoka, Masahiro; Nakagawa, Kazuhiko

doi:10.1002/ijc.23253

Public

Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk

Published in International Journal of Cancer • Nov 21, 2007

Authors:

Takeshi Yoshida

Isamu Okamoto

Takafumi Okabe

Abstract

Molecular inhibition of the epidermal growth factor receptor (EGFR) is a promising anticancer strategy, and monoclonal antibodies (mAbs) to EGFR are undergoing extensive evaluation in preclinical and clinical trials. However, the effects of anti-EGFR mAbs on EGFR signaling have remained unclear. We ...

View

Paywalled

Subject

Cetuximab

Epidermal growth factor receptor

Protein kinase B

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Subject

Generate AI Take for this paper

Discussions